A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome

Trial Profile

A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Bemcentinib (Primary) ; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BerGenBio
  • Most Recent Events

    • 29 Jan 2018 According to a BerGenBio media release, data from this study is presented at the ASCO-SITC Clinical Immuno-Oncology Symposium 2018.
    • 11 Dec 2017 According to a BerGenBio ASA media release, the second part of the trial (an expansion cohorts as a monotherapy as well as in combination with low dose chemotherapy) is ongoing and will report the updated date in 2018.
    • 11 Dec 2017 According to a BerGenBio ASA media release, presented updated data (n=35) at the 59th American Society of Hematology Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top